乳腺癌的化疗进展PPT.ppt

乳腺癌的化疗进展;乳腺癌化疗的历史回顾;TX方案与AC方案比较;TX方案与AC方案比较;Phase III trial comparing AC with TC; Nab-paclitaxel (ABI-007, Abraxane) 是将paclitaxel包裹在白蛋白里。;Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy ;The trastuzumab and vinorelbine or taxane study. ;A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.;A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.;A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.;Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.;Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: ;Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study ;A phase II clinical trial of ZD1839 (Iressatrade mark) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.;A phase II clinical trial of ZD1839 (Iressatrade mark) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.;A phase II clinical trial of ZD1839 (Iressatrade mark) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.;Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.;Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.;Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplat